Literature DB >> 8236970

Cardiac ultrasonography in structural abnormalities and arrhythmias. Recognition and treatment.

M M Brook1, N H Silverman, M Villegas.   

Abstract

Fetal cardiac ultrasonography has become an important tool in the evaluation of fetuses at risk for cardiac anomalies. It can both guide prenatal treatment and assist the management and timing of delivery. We recommend that a fetal echocardiogram be done when there is a family history of congenital heart disease; maternal disease that may affect the fetus; a history of maternal drug use, either therapeutic or illegal; evidence of other fetal abnormalities; or evidence of fetal hydrops. The optimal timing of evaluation is 18 to 22 weeks' gestation. An entire range of structural cardiac defects can be visualized prenatally, including atrioventricular septal defect, ventricular septal defect, cardiomyopathy, ventricular outlet obstruction, and complex cardiac defects. The outcome for a fetus with a recognized abnormality is unfavourable, with less than 50% surviving the neonatal period. Fetal cardiac arrhythmias are also a common occurrence, 15% in the series described here. Premature atrial or ventricular contractions are most commonly seen and usually require no treatment. Supraventricular tachycardia can result in hydrops and require in utero treatment to prevent fetal demise. Complete heart block, particularly in association with structural heart disease, has a poor prognosis for fetal survival.

Entities:  

Mesh:

Year:  1993        PMID: 8236970      PMCID: PMC1011341     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  62 in total

1.  Maternal antibodies against fetal cardiac antigens in congenital complete heart block.

Authors:  P V Taylor; J S Scott; L M Gerlis; E Esscher; O Scott
Journal:  N Engl J Med       Date:  1986-09-11       Impact factor: 91.245

2.  Echocardiography in the investigation of anterior abdominal wall defects in the fetus.

Authors:  D C Crawford; M G Chapman; L D Allan
Journal:  Br J Obstet Gynaecol       Date:  1985-10

3.  Doppler echocardiographic studies of diastolic function in the human fetal heart: changes during gestation.

Authors:  K L Reed; D J Sahn; S Scagnelli; C F Anderson; L Shenker
Journal:  J Am Coll Cardiol       Date:  1986-08       Impact factor: 24.094

4.  Spectrum of congenital heart disease detected echocardiographically in prenatal life.

Authors:  L D Allan; D C Crawford; R H Anderson; M Tynan
Journal:  Br Heart J       Date:  1985-11

5.  Diagnosis of fetal arrhythmias using echocardiographic and Doppler techniques.

Authors:  L Steinfeld; H L Rappaport; H C Rossbach; E Martinez
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

6.  Fetal ventricular pacing for hydrops secondary to complete atrioventricular block.

Authors:  R J Carpenter; J F Strasburger; A Garson; R T Smith; R L Deter; H T Engelhardt
Journal:  J Am Coll Cardiol       Date:  1986-12       Impact factor: 24.094

7.  Fetal echocardiography: results in high-risk patients.

Authors:  G G Sandor; D Farquarson; B Wittmann; T C Chow; A E Lau
Journal:  Obstet Gynecol       Date:  1986-03       Impact factor: 7.661

8.  Echocardiographic diagnosis and intravenous digoxin management of fetal tachyarrhythmias and congestive heart failure.

Authors:  J W Wiggins; W Bowes; W Clewell; M Manco-Johnson; D Manchester; R Johnson; K Appareti; R R Wolfe
Journal:  Am J Dis Child       Date:  1986-03

9.  Doppler echocardiography in the diagnosis and management of persistent fetal arrhythmias.

Authors:  J F Strasburger; J C Huhta; R J Carpenter; A Garson; D G McNamara
Journal:  J Am Coll Cardiol       Date:  1986-06       Impact factor: 24.094

10.  Pulmonary atresia in prenatal life.

Authors:  L D Allan; D C Crawford; M J Tynan
Journal:  J Am Coll Cardiol       Date:  1986-11       Impact factor: 24.094

View more
  1 in total

1.  Diagnosis and management of non-immune hydrops in the newborn.

Authors:  C K Phoon
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1994-09       Impact factor: 5.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.